Lv78
4650 积分 2022-03-19 加入
好网站,坚持每天签到,朴素的支持方式
Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy
20小时前
待确认
Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies
20小时前
已完结
CBP/p300, a promising therapeutic target for prostate cancer
1天前
已完结
Personalized intensification of treatment for hormone-sensitive prostate cancer
2天前
已完结
The evolving landscape of tissue‐agnostic therapies in precision oncology
3天前
已完结
Homogeneous multi-payload antibody–drug conjugates
3天前
已完结
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
3天前
已完结
Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges
3天前
已完结
Targeting genomic instability in cancer
3天前
已完结
Antibody-drug conjugates in precision oncology
3天前
已完结